Is it Time to Dump Oramed Pharmaceuticals, Inc. (ORMP) Stock After it Has Fallen 5.83% in a Week?

Overall market sentiment has been down on Oramed Pharmaceuticals, Inc. (ORMP) stock lately. ORMP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Oramed Pharmaceuticals, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ORMP!

See Full ORMP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ORMP Stock Today?

Oramed Pharmaceuticals, Inc. (ORMP) stock is trading at $1.94 as of 10:00 AM on Friday, Jan 27, a rise of $0.01, or 0.48% from the previous closing price of $1.93. The stock has traded between $1.90 and $1.95 so far today. Volume today is less active than usual. So far 167,714 shares have traded compared to average volume of 2,566,539 shares. To screen for more stocks like Oramed Pharmaceuticals, Inc. click here.

More About Oramed Pharmaceuticals, Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. Click Here to get the full Stock Report for Oramed Pharmaceuticals, Inc. stock.